Cost-Effectiveness of Granulocyte Colony–Stimulating Factor Prophylaxis for Febrile Neutropenia in Breast Cancer in the United Kingdom
Author:
Funder
Amgen
Publisher
Elsevier BV
Subject
Public Health, Environmental and Occupational Health,Health Policy
Reference38 articles.
1. Mortality, morbidity, and cost associated with febrile neutropenia in adult cancer patients;Kuderer;Cancer,2006
2. Predictors of reduced dose intensity in patients with early-stage breast cancer receiving adjuvant chemotherapy;Shayne;Breast Cancer Res Treat,2006
3. Filgrastim (r-metHuG-CSF): the first 10 years;Welte;Blood,1996
4. A randomized double-blind multicenter phase III study of fixed-dose single-administration pegfilgrastim versus daily filgrastim in patients receiving myelosuppressive chemotherapy;Green;Ann Oncol,2003
5. First and subsequent cycle use of pegfilgrastim prevents febrile neutropenia in patients with breast cancer: a multicenter, double-blind, placebo-controlled phase III study;Vogel;J Clin Oncol,2005
Cited by 48 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Cost of Pegfilgrastim for the Prophylaxis of Chemotherapy-induced Febrile Neutropenia in Patients with Breast Cancer Receiving Perioperative Chemotherapy in Daily Practice in Japan: A Posthoc Analysis in a Single-center Retrospective Study;YAKUGAKU ZASSHI;2024-09-01
2. Cost-effectiveness analysis of granulocyte colony-stimulating factors for the prophylaxis of chemotherapy-induced febrile neutropenia in patients with breast cancer in Taiwan;PLOS ONE;2024-06-10
3. An observational, prospective, open label, multicenter study to evaluate the safety and effectiveness of pegfilgrastim as secondary prophylaxis to decrease the incidence of febrile neutropenia in Korean female patients with breast cancer;The Breast;2023-12
4. Cost-effectiveness of granulocyte colony-stimulating factors (G-CSFs) for the prevention of febrile neutropenia (FN) in patients with cancer;Supportive Care in Cancer;2023-09-20
5. The efficacy of Mecapegfilgrastim therapy in the primary prevention of concurrent chemoradiotherapy-induced neutropenia;Journal of Radiation Research and Applied Sciences;2023-09
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3